# Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients

> **NCT05963282** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9870 (actual)

## Conditions studied

- de Novo Heart Failure

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05963282
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-29
- **Primary completion:** 2022-07-19
- **Final completion:** 2022-07-19
- **Target enrollment:** 9870 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05963282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05963282, "Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05963282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*